Breast Cancer | Specialty

The breast cancer condition center is a comprehensive resource for clinical news and expert insights on breast cancer. Read more at OncLive.

ADCs in HER2-Low Breast Cancer: Insights From DESTINY-Breast04, TROPiCS-02, and TROPION-Breast02

January 22nd 2025

Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates.

Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance

January 21st 2025

David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.

Dr Zhang on the Efficacy of SIM0270 Plus Everolimus in ER+/HER2− Advanced Breast Cancer

January 21st 2025

Jian Zhang, MD, discusses SIM0270, a brain-penetrant oral SERD, in combination with everolimus, in ER-positive, HER2-negative advanced breast cancer.

Exploring 1L and 2L CDK4/6 Inhibitors + Endocrine Therapies

January 21st 2025

Panelists discuss how first- and second-line treatment options for HR+ advanced/metastatic breast cancer, particularly the use of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy, are influenced by clinical factors such as bone metastasis, visceral crisis, and molecular phenotype, while also reviewing the latest clinical trial data, real-world outcomes, and comparative efficacy of ribociclib, abemaciclib, and palbociclib.

FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS

January 20th 2025

The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.

In-House Comprehensive Genomic Profiling: Expert Insight Into Balancing Benefits and Challenges

January 20th 2025

Panelists discuss how in-house comprehensive genomic profiling (CGP) testing offers key benefits like reduced turnaround times, direct control over processes, and immediate access to testing resources. However, significant challenges include substantial initial capital investment, the need for specialized staff recruitment and retention, and ongoing equipment maintenance requirements. Health care facilities must carefully weigh these trade-offs, considering their patient volume, existing infrastructure, and financial capabilities before implementing in-house CGP services.

Centralized vs Decentralized Biomarker Testing: Workflow, Control, and Collaboration Insights

January 20th 2025

Panelists discuss how centralized biomarker testing outsources analysis to specialized laboratories while decentralized testing occurs in-house. In-house testing offers tighter workflow control and closer pathology collaboration but requires more resources, whereas send-out testing leverages external expertise.

The OncFive: Top Oncology Articles for the Week of 1/12

January 18th 2025

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

January 17th 2025

The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.

When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis

January 16th 2025

Panelists discuss how comprehensive genomic testing may not be practical for well-understood tumors with established treatment pathways. Narrow panel testing is preferred when specific mutations guide therapy (like EGFR in lung cancer) or when time/cost constraints exist.

The Importance of Broad Biomarker Testing: Uncovering Actionable Targets Across Tumor Types

January 16th 2025

Panelists discuss how comprehensive biomarker testing enables detection of actionable mutations across cancer types, informing targeted therapy selection. This broad molecular profiling approach can reveal treatment opportunities regardless of tumor origin.

Dr Nathanson on BRCA1/2 Reversion Mutations in Response to Therapy in Breast Cancer

January 16th 2025

Katherine L. Nathanson, MD, discusses the identification of reversion mutations in BRCA1/2 in response to therapy among patients with breast cancer.

Dr Graff on Fertility Preservation Strategies in Breast Cancer

January 15th 2025

Stephanie L. Graff, MD, FACP, FASCO, discusses current strategies for fertility preservation in patients with breast cancer.

Dr Graff on the Efficacy and Safety of GnRH Agonists for Premenopausal Women With Breast Cancer

January 15th 2025

Stephanie L. Graff, MD, FACP, FASCO, discusses data supporting the use of GnRH agonists for premenopausal women with breast cancer undergoing chemotherapy.

Precision Medicine in Breast Cancer: Evolving Paradigms in HER2 Testing and Clinical Implications

January 15th 2025

Panelists discuss how evolving HER2 classification methods and recent trial data are reshaping treatment approaches for advanced breast cancer, particularly regarding the clinical significance of HER2-low and ultralow categories.

Current Practices for Targeted Therapies and Molecular Testing for HR+/HER2- Metastatic Breast Cancer

January 14th 2025

Panelists discuss how the latest NCCN guidelines for targeted therapies and biomarker testing in advanced/metastatic breast cancer highlight the importance of biomarker-driven approaches, with particular emphasis on the need for next-generation sequencing testing in the first-line setting, the implications of HER2-low classification, and how the recent FDA approval of a PI3K inhibitor may impact testing practices and treatment strategies.

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

January 13th 2025

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.

Dr Huppert on Survival Outcomes of Patients With Metastatic Breast Cancer and Leptomeningeal Disease

January 9th 2025

Laura A. Huppert, MD, discusses survival outcomes of patients with metastatic breast cancer and leptomeningeal disease according to disease subtype.

Dr Geyer on the Efficacy of Perioperative Atezolizumab Plus Chemotherapy in Stage II/III TNBC

January 8th 2025

Charles E. Geyer, Jr., MD, discusses the efficacy and safety of perioperative atezolizumab plus chemotherapy in stage II/III triple-negative breast cancer.

Dr LeVee on Immune-Related AEs Associated With ICIs in Early Breast Cancer

January 6th 2025

Alexis LeVee, MD, discusses immune-related adverse effects in patients with early breast cancer treated with immune checkpoint inhibitors.